Ces radiol. 2015, 69(2):137-141 | DOI: 10.55095/CesRadiol2015/021

Irreversible electroporation (IRE) of tumorsOriginal article

Josef Hořejš1, Zdeněk Krška2, David Hoskovec2, Lukáš Lambert1, Vladimír Černý1, Jiří Jahoda1, Luboš Petruželka3, Tomáš Krechler4, Petr Kříž5
1 Radiodiagnostická klinika 1. LF UK a VFN, Praha
2 I. chirurgická klinika 1. LF UK a VFN, Praha
3 Onkologická klinika 1. LF UK a VFN, Praha
4 IV. interní klinika 1. LF UK a VFN, Praha
5 Klinika anesteziologie a resuscitace 1. LF UK a VFN, Praha

Aim: To show the safety and clinical usefulness of IRE.

Methods: A total of 23 pancreatic adenocarcinomas, two liver mets of colorectal carcinoma and 1 renal adenocarcinoma have undergone IRE percutaneously under CT control or during laparotomy with US guidance.

Results: IRE is safe method, 30 days mortality 0. There is no significant prolongation of survival in the group of unresectable pancreatic cancer. Survival in the group of pancreatic cancer is 10 months.

Conclusion: IRE is a safe and useful ablative method, especially with the tumors nearby critical structures.

Keywords: irreversible electroporatin, pancreatic adenokarcinoma, radiofrequency ablation
Grants and funding:

Podporováno grantem IGA NT/ 13263-4.

Accepted: April 20, 2015; Published: June 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hořejš J, Krška Z, Hoskovec D, Lambert L, Černý V, Jahoda J, et al.. Irreversible electroporation (IRE) of tumors. Ces radiol. 2015;69(2):137-141. doi: 10.55095/CesRadiol2015/021.
Download citation

References

  1. Pezzilli R, Serra C, Ricci C, et al. Radiofrequency ablation for advanced ductal pancreatic carcinoma: is this approach beneficial for our patients? A systematic review. Pancreas 2011; 40: 163-165. Go to original source... Go to PubMed...
  2. Lygidakis NJ, Sharma SK, Papastratis P, et al. Microwave ablation in locally advanced pancreatic carcinoma-a new look. Hepatogastroenterology 2007; 54: 1305-1310.
  3. Li J, Chen X, Yang H, et al. Tumour cryoablation combined with palliative bypass surgery in the treatment of unresectable pancreatic cancer: a retrospective study of 142 patients. Postgrad Med J 2011; 87: 89-95. Go to original source... Go to PubMed...
  4. Válek V, Kala Z, Kiss I, et al. Maligní ložiskové procesy jaterní. Praha: Grada Publishing 2006; 340-354.
  5. Thomson KR, Cheung W, Ellis SJ, et al. Investigation of safety of irreversible elektroporation in humans. J Vasc Interv Radiol 2011; 22: 611-621. Go to original source... Go to PubMed...
  6. Rubinsky B. Irreversible electroporation in medicine. Medicine Technol. Cancer Res Treat 2007; 6(4): 307-312. Go to original source... Go to PubMed...
  7. Davalos RV, Mir LM, Rubinsky B. Tissue ablation with irreversible electroporation. Annals of Biomedical Engineering 2005; 33(2): 223-231. Go to original source... Go to PubMed...
  8. Krška Z, Hoskovec D, Petruželka L. Chirurgická onkologie. Praha: Grada Publishing 2014; 473-513.
  9. D'Onofrio M, Barbi E, Girelli R, et al. Radiofrequency ablation of locally advanced pancreatic adenocarcinoma: an overview. World J Gastroenterol 2010; 16: 3478-3483. Go to original source... Go to PubMed...
  10. Bower M, Sherwood L, Li Y, Martin R. Irreversible electroporation of the pankreas: definitive local therapy without systemic effect. J Surg Oncol 2011; 104: 22-28. Go to original source... Go to PubMed...
  11. Narayanan G, Hosein P, Arora G, et al. Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. J Vasc Interv Radiol 2012; 23: 1613-1621. Go to original source... Go to PubMed...
  12. Martin RC II, McFarland K, Ellis S, Velanovich V. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. J Am Coll Surg 2012; 215: 361-369. Go to original source... Go to PubMed...
  13. Pech M, Janitzky A, Wendler JJ, et al. Irreversible electroporation of renal cell carcinoma: a first-in-man-phase I clinical study. Cardiovasc Intervent Radiol 2011; 34: 132-138. Go to original source... Go to PubMed...

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.